Biorica International Corp.

CLOSEOUT LETTER Biorica International Corp. MARCS-CMS 659194 — April 09, 2024 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Dietary Supplements Recipient: Recipient Name Jacqueline Baxas Recipient Title President Biorica International Corp. 4310 Sheridan St., Suite 202 Hollywood , FL 33021 United States info@biorica.biz Issuing Office: Center for Food Safety and Applied Nutrition (CFSAN) United States Secondary Issuing Offices United States Dear Ms. Baxas: The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter #659194, issued August 4, 2023. Based on our evaluation, it appears you have addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Carrie Lawlor Branch Chief Dietary Supplement and Labeling Assessment Branch Division of Enforcement Office of Compliance Center for Food Safety and Applied Nutrition Content current as of: 04/17/2024 Regulated Product(s) Dietary Supplements